Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Radiation therapy for mesenterial lymph nodes for malignant lymphoma

General

Indications

Mesenterial lymph nodes are a separate lymph node region in the Ann Arbor system. The region is large, and characteristically lesions in this area have much internal movement.  

Curative radiation therapy

  • Limited stages of Hodgkin's lymphoma (stage IA/IIA) with mesenterial involvement is rare, and central infradiaphragmal disease itself is a risk factor. According to guidelines, these patients are given 4 ABVD cycles followed by consolidative radiation therapy to the involved field, but this is based on the premise that involved areas can be included in a reasonable field with adequate margin. If this is not the case, for example due to large tumor masses, the position of the kidneys etc., chemotherapy for advanced disease should be given, and radiation therapy considered for residual lesions.  
  • For localized stages of nodular lymphocyte-rich Hodgkin's lymphoma (stage IA/IIA) without risk factors, radiation therapy alone is given to the involved area with margin (involved field) without previous chemotherapy. This is based on the premise that involved areas can be included in a reasonable field with adeqate margin. If this is not the case, for example due to large tumor masses, the position of the kidneys etc., chemotherapy for advanced disease should be given, and radiation therapy considered for residual lesions.
  • Special guidelines apply for children and adolescents up to 18 years with Hodgkin's lymphoma.
  • For residual tumor of Hodgkin's lymphoma after full chemotherapy for advanced Hodgkin's lymphoma (6-8 ABVD, 8 BEACOPP or equivalent), consolidative radiation therapy to the residual tumor with margin is considered.  
  • For localized stages of aggressive lymphomas (stage I-II1), consolidative radiation therapy is given after chemotherapy (CHOP-based or equivalent) to the original tumor-involved area with margin (involved field). This is based on the premise that involved areas can be included in a reasonable field with adeqate margin. If this is not the case, for example due to large tumor masses, the position of the kidneys etc., chemotherapy for advanced disease should be given, and radiation therapy considered for residual lesions.
  • With residual tumor of aggressive lymphomas after full chemotherapy (6-8 CHOP-based cycles or equivalent), consolidative radiotherapy to the residual tumor with margin is considered.
  • For indolent lymphomas with localized disease (stage I-II1), radiation therapy alone is given to the involved area with margin (involved field). This is based on the premise that involved areas can be included in a reasonable field with adeqate margin. If this is not the case, for example due to large tumor masses, the position of the kidneys etc., chemotherapy for advanced disease should be given, and radiation therapy considered for residual lesions.

Palliative radiation therapy

  • As palliative radiation therapy, the method is based on guidelines for curative treatment with individual modifications.

     

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2016